Leveraging DNA Methylation For Life




We develop research tools and molecular diagnostic products to advance epigenetics and fulfill the promise of personalized medicine.

Company Highlights

Qiagen to market MethylScreen™ Kits for research use under a non-exclusive license.

Orion and Novartis collaborate to discover and develop novel epigenetic biomarkers.

Orion engaged in consortium with the Malaysian Palm Oil Board to study epigenetic underpinnings of desirable traits in two species of oil palm.

MethylScope® technology enables genome-wide DNA methylation profiling, allowing the identification of DNA biomarkers important to epigenetic studies.

MethylScreen technology validates putative epigenetics biomarkers and precisely identifies epigenetics biomarkers in sample.